Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Dec;2(4):317–324. doi: 10.18383/j.tom.2016.00175

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 The Authors. Published by Grapho Publications, LLC

This is an open access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Figure 1. — Patient ML-10 #1. Representative baseline (BL; A–C) and early-therapy assessment (ETA; D–F) contrast-enhanced (CE) magnetic resonance imaging (MRI), [¹⁸F]ML-10 standard uptake value (SUV), and positron emission tomography (PET)/CE-MRI fusion images for a 72-year-old male with a new glioblastoma multiforme (GBM) diagnosis. All images are shown coregistered to the patient's BL CE-MRI. BL CE-MRI (A) shows enhancement in the region of the right periventricular white matter/splenium of corpus callosum and left insular region. ETA CE-MRI (D) shows an increase in size and contrast enhancement consistent with progression. On PET, BL [¹⁸F]ML-10 SUV image (B) shows mild therapy-naive uptake (BL SUV_max = 0.54) located at the tumor site on PET/CE-MRI (C). The ETA [¹⁸F]ML-10 SUV image (E) shows increased [¹⁸F]ML-10 uptake (ETA SUV_max = 0.84) at the GBM site (F) consistent with increased apoptosis compared with BL.